% | $
Quotes you view appear here for quick access.

Immune Pharmaceuticals, Inc. Message Board

  • larshansson18 larshansson18 May 9, 2011 8:50 AM Flag

    Now we are on our way to ASCO

    Look out for the results for NP-1 in the abstracts publiched May 18 from ASCO.

    As management have stated in the last annual report the cream might well exceed the economic value of the whole cancer portefolio. We will become a "pain" CO, supported by an approved cancer drug. Not bad.

    Am I the only one that can not read the posts here? Any answers? :-) If this gets through it is obviuosly possible to write. Anyways.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Yahoo personal have fixed the problems for me and others so that we can read the posts again.

      So tomorrow we have May 18.

      National Cancer Institute, NCI, that conducted the phase II b trial and have made the submission to ASCO.

      The results are a "break through" for efficacy and the results have "bolstered" the partner negotiations, according to CEO in Epicept.

      Let's hope for some results where over 50% of the patients feel, at least,30% reduction in pain. We have a nice potential in the fact that the cream may have further efficacy when treatment is prolonged for additional weeks beyond 6 weeks treatment. Up to 6 weeks treatment every new week have added new efficacy on significantly basis versus placebo. FDA wants to have 8-12 weeks treatment depending on studied diagnosis. 8 for PHN and 12 for the broader neuropatic pain diagnosis.

      For a treatment with side effects longer treatment is an obstacle. The opposite seems to be the case for Amiket. :-)

0.35-0.03(-7.63%)3:52 PMEDT